Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34408852&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
A dataset for the analysis of antibody response to glycan alpha-Gal in individuals with immune-mediated disorders #MMPMID34408852
de la Fuente J; Urra JM; Contreras M; Pacheco I; Ferreras-Colino E; Doncel-Perez E; Fernandez de Mera IG; Villar M; Cabrera CM; Gomez Hernando C; Vargas Baquero E; Blanco Garcia J; Rodriguez Gomez J; Velayos Galan A; Feo Brito F; Gomez Torrijos E; Cabezas-Cruz A; Gortazar C
F1000Res 2020[]; 9 (?): 1366 PMID34408852show ga
Humans evolved by losing the capacity to synthesize the glycan Galalpha1-3Galbeta1-(3)4GlcNAc-R (alpha-Gal), which resulted in the development of a protective response mediated by anti-alpha-Gal IgM/IgG/IgA antibodies against pathogens containing this modification on membrane proteins. As an evolutionary trade-off, humans can develop the alpha-Gal syndrome (AGS), a recently diagnosed disease mediated by anti-alpha-Gal IgE antibodies and associated with allergic reactions to mammalian meat consumption and tick bites. However, the anti-alpha-Gal antibody response may be associated with other immune-mediated disorders such as those occurring in patients with COVID-19 and Guillain-Barre syndrome (GBS). Here, we provide a dataset (209 entries) on the IgE/IgM/IgG/IgA anti-alpha-Gal antibody response in healthy individuals and patients diagnosed with AGS, tick-borne allergies, GBS and COVID-19. The data allows correlative analyses of the anti-alpha-Gal antibody response with factors such as patient and clinical characteristics, record of tick bites, blood group, age and sex. These analyses could provide insights into the role of anti-alpha-Gal antibody response in disease symptomatology and possible protective mechanisms.
free
free
free
F1000Res 2020 ; 9 (?): 1366
